AR052156A1 - Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos - Google Patents

Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos

Info

Publication number
AR052156A1
AR052156A1 ARP050105207A ARP050105207A AR052156A1 AR 052156 A1 AR052156 A1 AR 052156A1 AR P050105207 A ARP050105207 A AR P050105207A AR P050105207 A ARP050105207 A AR P050105207A AR 052156 A1 AR052156 A1 AR 052156A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
substituted
neurological
treatment
Prior art date
Application number
ARP050105207A
Other languages
English (en)
Spanish (es)
Inventor
Synese Jolidon
Robert Narquizian
Roger David Norcross
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR052156A1 publication Critical patent/AR052156A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP050105207A 2004-12-15 2005-12-13 Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos AR052156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04106597 2004-12-15

Publications (1)

Publication Number Publication Date
AR052156A1 true AR052156A1 (es) 2007-03-07

Family

ID=35841863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105207A AR052156A1 (es) 2004-12-15 2005-12-13 Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos

Country Status (20)

Country Link
US (1) US7375226B2 (https=)
EP (1) EP1828200B1 (https=)
JP (1) JP4709849B2 (https=)
KR (1) KR100883003B1 (https=)
CN (1) CN100586951C (https=)
AR (1) AR052156A1 (https=)
AT (1) ATE457989T1 (https=)
AU (1) AU2005315914B2 (https=)
BR (1) BRPI0519054A2 (https=)
CA (1) CA2590316A1 (https=)
DE (1) DE602005019465D1 (https=)
ES (1) ES2338139T3 (https=)
IL (1) IL183592A0 (https=)
MX (1) MX2007006896A (https=)
NO (1) NO20072833L (https=)
NZ (1) NZ555476A (https=)
RU (1) RU2007121768A (https=)
TW (1) TWI299041B (https=)
WO (1) WO2006063709A1 (https=)
ZA (1) ZA200705044B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
EP2527328A1 (en) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP2393878B1 (de) 2009-02-06 2012-12-12 Styrolution GmbH Thermoplastische formmassen auf basis von styrolcopolymeren und polyamiden mit verbesserter witterungsbeständigkeit
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2806103A1 (en) * 2010-08-31 2012-03-08 Vanderbilt University Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
AU2012357169B2 (en) * 2011-12-22 2017-03-30 Merck Patent Gmbh Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104203951B (zh) * 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
WO2013138568A1 (en) * 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ-セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ-カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423847A1 (de) * 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
PL343435A1 (en) * 1998-03-06 2001-08-13 Janssen Pharmaceutica Nv Glycine transport inhibitors
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004037800A1 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
CN1874777B (zh) * 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
WO2005023261A1 (en) * 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Also Published As

Publication number Publication date
ATE457989T1 (de) 2010-03-15
NZ555476A (en) 2009-09-25
AU2005315914B2 (en) 2011-03-03
IL183592A0 (en) 2007-09-20
CN101076532A (zh) 2007-11-21
TWI299041B (en) 2008-07-21
KR100883003B1 (ko) 2009-02-12
DE602005019465D1 (de) 2010-04-01
ZA200705044B (en) 2008-09-25
AU2005315914A1 (en) 2006-06-22
EP1828200B1 (en) 2010-02-17
ES2338139T3 (es) 2010-05-04
WO2006063709A1 (en) 2006-06-22
KR20070086196A (ko) 2007-08-27
US7375226B2 (en) 2008-05-20
BRPI0519054A2 (pt) 2008-12-23
JP4709849B2 (ja) 2011-06-29
NO20072833L (no) 2007-07-17
JP2008523126A (ja) 2008-07-03
US20060128713A1 (en) 2006-06-15
CN100586951C (zh) 2010-02-03
RU2007121768A (ru) 2009-01-27
EP1828200A1 (en) 2007-09-05
CA2590316A1 (en) 2006-06-22
TW200634017A (en) 2006-10-01
MX2007006896A (es) 2007-06-26

Similar Documents

Publication Publication Date Title
AR052156A1 (es) Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos
AR054799A1 (es) Derivados de oxindol
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
AR049551A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO20072643L (no) Fenylpiperazinmethanonderivater
PE20110215A1 (es) Derivados de 4,5-dihidro-oxazol-2-ilo
CO5660289A2 (es) Derivados de 4-piridinilmetilsulfonamida como agentes fungicidas para proteccion de plantas
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
ECSP077394A (es) Compuestos aromáticos de arilsulfonilmetil o arilsulfonamida sustituida apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
PE20051152A1 (es) Antagonistas del receptor de acetilcolina muscarinico m3
PE20091187A1 (es) Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6
PE20080206A1 (es) Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina
CO4990949A1 (es) Derivados de imidazol y su preparacion .
AR055666A1 (es) Inhibidores inntr
UY26147A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
AR052553A1 (es) Derivados de benzoil -tetrahidropiridina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal